Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma
- Study showed signs of clinical activity, but failed to meet the primary endpoint of the Phase 2 study
- Two ongoing phase 1 trials are exploring the intravenous administration of two different MVA-based brachyury-targeting investigational products in chordoma.
COPENHAGEN, Denmark, December 18, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced top-line results from a Phase 2 clinical study evaluating the targeted immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma, a rare cancer occurring in the base of the skull and spine. While the study failed to meet its primary endpoint, it provided evidence of clinical activity.
The Phase 2 study enrolled 29 patients, which were treated with a combination of the prime-boost vaccine candidate, BN-Brachyury and the current standard of care, radiation therapy. Whereas radiation has been shown to inflame the tumor, thereby releasing cancer antigens, BN-Brachyury has been designed to teach T cells to attack and kill brachyury-expressing tumor cells. Patients were monitored over a period of 12 months after radiation therapy, a timeframe during which historical controls show an objective response rate (ORR) of less than 5% with radiation alone. The overall goal of the study was to achieve four patients with objective responses, corresponding to an ORR of approximately 14% for all patients enrolled.
Two patients achieving objective responses were observed in the study, as measured by the predefined conventional assessment criteria (RECIST) according to the study protocol. In addition, 19 patients have stable disease, while the rest progressed, or left the study before the assessment was performed. The RECIST criteria assumes tumors are spherical and assesses their size by measuring the tumor diameter. This method may, however, underestimate the chordoma tumor shrinkage, as a retrospective analysis of six of the patients enrolled into the study revealed four of these patients had an objective response when tumor shrinkage was evaluated by a volumetric assessment. These intriguing signs of clinical efficacy are also supported by two chordoma patients that have recorded either a volumetric objective response, or a symptomatic response following the intravenous administration of BN-Brachyury in a separate on-going trial.
While no further studies of BN-Brachyury administered subcutaneously are planned, the signs of clinical efficacy that have been observed support brachyury as a potentially important immunotherapy target, particularly for chordoma. The Company is now looking to adapt ongoing trials to investigate MVA-based vaccines encoding brachyury administered intravenously - a promising approach designed to utilize broader aspects of the immune response while improving T cell activation and function.
“Chordoma is known for its refractoriness to all treatments investigated so far. The observation of some hints of efficacy with our immunotherapy approach is encouraging enough for us to continue with our efforts to develop a new treatment for this highly unmet medical need,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, email@example.com, Tel: +1 781 686 9600
Company Announcement no. 53 / 2020
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS15.1.2021 16:20:00 CET | Press release
Bid procedure, 2021-01-18BillsSWEDISH T-BILL: SE0014555991. 2021-06-16 SWEDISH T-BILL: SE0014808747, 2021-09-15 Bid date2021-01-18Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0014555991: 500 mln SEK +/-250 mln SEK SE0014808747: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0014555991: 500 mln SEK per bid SE0014808747: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-01-20Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-15 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS15.1.2021 16:20:00 CET | Press release
Anbudsförfarande kommuner och regioner, 2021-01-19BondsFloating-rate Notes(FRN) issued in SEK by Municipalities or Regions with maturity in: 2023 The following issuers are accepted for delivery: Borås Stad Göteborgs Stad Helsingborgs Stad Huddinge Kommun Lunds Kommun Malmö Stad Norrköpings Kommun Region Skåne Stockholms Stad Region Stockholm Sundsvalls Kommun Södertälje Kommun Täby Kommun Uppsala Kommun Västerås Stad Örebro Kommun Östersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2021-01-08BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2021-01-19Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 1000 +/- 1000 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from
CONDITIONS FOR PURCHASES OF CORPORATE BONDS15.1.2021 16:20:00 CET | Press release
Bid procedure, 2021-01-20BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: AKELIUS RESIDENTIAL AB: XS1692931980, 2021-10-04 AKELIUS RESIDENTIAL AB: XS1889043359, 2023-10-03 FASTIGHETS AB BALDER: SE0013359726, 2022-07-01 FASTIGHETS AB BALDER: SE0012675940, 2022-01-28 WILLHEM AB: SE0012193985, 2025-02-22 WILLHEM AB: SE0011088921, 2022-01-11 LUNDBERGFORETAGEN AB: SE0012676666, 2024-12-06 LUNDBERGFORETAGEN AB: SE0012676609, 2025-11-13 TELE2 AB: XS2187707463, 2025-06-10 TELE2 AB: XS1571151627, 2023-02-24 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2020-12-20Bid date2021-01-20Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1692931980: 30 mln SEK +/-30 mln SEK XS1889043359: 30 mln SEK +/-30 mln SEK SE0
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS15.1.2021 16:20:00 CET | Press release
Bid procedure, 2021-01-21BondsSTADSHYPOTEK AB: 1590. SE0012676690. 2025-09-03 NORDEA HYPOTEK AB: 5534, SE0012230415, 2024-09-18 SKANDINAVISKA ENSKILDA: 576, SE0010049841, 2023-12-20 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SWEDBANK HYPOTEK AB: 194, SE0012142206, 2024-09-18 Bid date2021-01-21Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1590: 1500 mln SEK +/-500 mln SEK 5534: 1300 mln SEK +/-500 mln SEK 576: 900 mln SEK +/-450 mln SEK 2312: 400 mln SEK +/-200 mln SEK 518: 800 mln SEK +/-400 mln SEK 146: 800 mln SEK +/-400 mln SEK 194: 1300 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)1590: 1500 mln SEK per bid 5534: 1300 mln SEK per bid 576: 900 mln SEK per bid 2312: 400 mln SEK per bid 518: 800 mln SEK per bid 146: 800 mln SEK per bid 194: 1300 mln SEK per bid Lowest permitted bid volume
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS15.1.2021 16:20:00 CET | Press release
Bid procedure, 2021-01-22BondsSWEDEN I/L BOND: 3112. SE0008014062. 2026-06-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-01-22Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3112: 500 mln SEK +/-250 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3112: 500 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2021-01-26Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-15 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be r
Nykredit Bank A/S är nytt emissionsinstitut under Klöverns icke-säkerställda MTN-program15.1.2021 13:30:00 CET | Pressemelding
Nykredit Bank A/S har genom ett avtal daterat den 14 januari 2021 tillträtt som emissionsinstitut under Klövern AB (publ)s icke-säkerställda MTN-program (”MTN-programmet”) i enlighet med de allmänna villkoren för MTN-programmet ursprungligen daterade den 4 februari 2020 och såsom ändrade den 6 oktober 2020. Övriga emissionsinstitut under MTN-programmet är Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank Abp och Swedbank AB (publ). Mer information om MTN-programmet finns på Klöverns webbplats (www.klovern.se). Klövern AB (publ) För ytterligare information, vänligen kontakta: Jens Andersson, Finanschef, 076-855 67 02, firstname.lastname@example.org Rutger Arnhult, VD, 070-458 24 70, email@example.com Lars Norrby, IR, 076-777 38 00, firstname.lastname@example.org Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterat på Nasdaq Stockholm. Ytterligare information finns på www.klovern.se. Klövern AB (publ), Bredgränd 4,
Nykredit Bank A/S is new dealer under Klövern’s unsecured MTN Program15.1.2021 13:30:00 CET | Press release
Nykredit Bank A/S has through an agreement dated on 14 January 2021 acceded to Klövern AB (publ)’s unsecured MTN program (the ”MTN Program”) as dealer in accordance with the general terms and conditions of the MTN Program originally dated on 4 February 2020 and as amended on 6 October 2020. The other dealers under the MTN Program are Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank Abp and Swedbank AB (publ). Further information about the MTN Program can be found on Klövern’s website (www.klovern.se). Klövern AB (publ) For additional information, please contact: Jens Andersson, Head of Finance, +46 (0)76-855 67 02, email@example.com Rutger Arnhult, CEO, +46 (0)70-458 24 70, firstname.lastname@example.org Lars Norrby, IR, +46 (0)76-777 38 00, email@example.com Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se. Klö